SCHEMBL6155049

SCHEMBL6155049

Cc1cc(NC2CCNCC2)ccc1C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.44
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44
KIT P10721 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.43
P2RX7 Q99572 1/20 0.42
BRD4 O60885 2/20 0.41
ATAD2 Q6PL18 2/20 0.41
SYK P43405 3/20 0.41
KCNH2 Q12809 2/20 0.41
MAPK3 P27361 1/20 0.41
MAPK1 P28482 1/20 0.41
AURKB Q96GD4 1/20 0.41
RIPK2 O43353 1/20 0.40
HTR6 P50406 2/20 0.39
EML4 Q9HC35 1/20 0.39
ALK Q9UM73 1/20 0.39
MEN1 O00255 1/20 0.39
CYP2D6 P10635 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153421 0.84 AURKA (0.45) FLT3AURKARPS6KB1SIRT2P2RX7
SCHEMBL6156769 0.83 ROCK2 (0.47) AURKARPS6KB1SIRT2P2RX7SYK
SCHEMBL6153710 0.83 RPS6KB1 (0.44) FLT3AURKARPS6KB1SIRT2P2RX7
SCHEMBL6153679 0.83 HTR4 (0.48) FLT3AURKARPS6KB1KITSIRT2
SCHEMBL6154975 0.83 RPS6KB1 (0.42) FLT3AURKARPS6KB1SIRT2P2RX7
SCHEMBL29972939 0.82 POLB (0.49) FLT3RPS6KB1KITSYKRIPK2
SCHEMBL6154413 0.80 IRAK4 (0.48)
SCHEMBL6153513 0.80 SYK (0.46) FLT3AURKARPS6KB1KITSIRT2
SCHEMBL4144350 0.79 IRAK4 (0.45) AURKARPS6KB1SIRT2P2RX7BRD4
SCHEMBL6154140 0.79 HTR4 (0.45) FLT3RPS6KB1KITSYKMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 FLT3 2536/4885AURKA 2136/4885RPS6KB1 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.